Syncona was the major investor in iOnctura having invested €30m ($32.2m) for a 23% stake in the company. Image Credit: eamesBot / Shutterstock.
Swiss biopharma iOnctura has raised €80m ($85.8m) in Series B financing to fund the Phase II clinical trials for its two lead cancer therapies, roginolisib and cambritaxestat.
The PI3K class of drugs have faced a setback in recent years after the FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously recommended that “future approvals of PI3K inhibitors for hematologic malignancy indications be supported by randomised trial data”, in 2022. The decision was based on high levels of fatal adverse events (AEs) and high rates of toxicity associated with the drug class.
See Also:SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast CancerHER2- Breast Cancer): Likelihood of Approval
The therapy’s safety and pharmacokinetics are being evaluated in a Phase I/II study (NCT05586516) in patients with metastatic pancreatic cancer. The trial’s primary endpoint is the incidence of treatment-emergent side effects over a year.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.